Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.